Investments
55Portfolio Exits
20Funds
5About Altitude Life Science Ventures
Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies within markets with significant demand and growth potential, and then backs the highest-quality teams in those markets to build defensible, strong, and long-term businesses. At Altitude, our scope of investment opportunities extends beyond prescription drugs to any commercial application of proprietary technology that originates from a key advance in biology or chemistry.
Latest Altitude Life Science Ventures News
Jun 7, 2023
(Mozart Photo)New funding: Seattle biotech company Mozart Therapeutics announced $25 million in new funding Wednesday to further its development of therapies for celiac and other autoimmune conditions.The therapy: The fresh cash will be used to accelerate the development of MTX-101, Mozart’s leading drug candidate.Other competitors include GentiBio, which is building operations in Boston and Seattle, Egle Therapeutics, TRex Bio, and Avotres.The funding: The extended Series A round includes participation from Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises.Previous backers include Mozart investors ARCH Venture Partners, Sofinnova Partners, Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Altitude Life Science Ventures Investments
55 Investments
Altitude Life Science Ventures has made 55 investments. Their latest investment was in Generate Biomedicines as part of their Series C on September 9, 2023.
Altitude Life Science Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/14/2023 | Series C | Generate Biomedicines | $273M | No | 4 | |
6/7/2023 | Series A - II | Mozart Therapeutics | $25M | No | 8 | |
3/9/2023 | Series C | Ring Therapeutics | $86.5M | No | Alexandria Venture Investments, CJ Investment, Flagship Pioneering, Invus Group, Kyowa Kirin, Partners Investment, T. Rowe Price, Undisclosed Investors, and UPMC Enterprises | 2 |
11/28/2022 | Series C | |||||
10/11/2022 | Series B |
Date | 9/14/2023 | 6/7/2023 | 3/9/2023 | 11/28/2022 | 10/11/2022 |
|---|---|---|---|---|---|
Round | Series C | Series A - II | Series C | Series C | Series B |
Company | Generate Biomedicines | Mozart Therapeutics | Ring Therapeutics | ||
Amount | $273M | $25M | $86.5M | ||
New? | No | No | No | ||
Co-Investors | Alexandria Venture Investments, CJ Investment, Flagship Pioneering, Invus Group, Kyowa Kirin, Partners Investment, T. Rowe Price, Undisclosed Investors, and UPMC Enterprises | ||||
Sources | 4 | 8 | 2 |
Altitude Life Science Ventures Portfolio Exits
20 Portfolio Exits
Altitude Life Science Ventures has 20 portfolio exits. Their latest portfolio exit was Neumora on September 15, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/15/2023 | IPO | Public | 4 | ||
6/5/2023 | Acq - Pending | 2 | |||
9/15/2021 | IPO | Public | 3 | ||
Date | 9/15/2023 | 6/5/2023 | 9/15/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acq - Pending | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 4 | 2 | 3 |
Altitude Life Science Ventures Fund History
5 Fund Histories
Altitude Life Science Ventures has 5 funds, including Altitude Life Science Ventures Side Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/22/2019 | Altitude Life Science Ventures Side Fund III | $50M | 1 | ||
3/19/2018 | Altitude Life Science Ventures III | ||||
4/28/2015 | Altitude Life Science Ventures II | ||||
4/27/2015 | Altitude Life Science Ventures Fund II | ||||
Altitude Life Science Ventures Fund IV |
Closing Date | 1/22/2019 | 3/19/2018 | 4/28/2015 | 4/27/2015 | |
|---|---|---|---|---|---|
Fund | Altitude Life Science Ventures Side Fund III | Altitude Life Science Ventures III | Altitude Life Science Ventures II | Altitude Life Science Ventures Fund II | Altitude Life Science Ventures Fund IV |
Fund Type | |||||
Status | |||||
Amount | $50M | ||||
Sources | 1 |
Altitude Life Science Ventures Team
1 Team Member
Altitude Life Science Ventures has 1 team member, including current Founder, David Maki.
Name | Work History | Title | Status |
|---|---|---|---|
David Maki | Founder | Current |
Name | David Maki |
|---|---|
Work History | |
Title | Founder |
Status | Current |
Loading...